Actively Enrolling Diabetic Retinopathy and DME Clinical Trials

• Home
• Clinical Trials
• Actively Enrolling Diabetic Retinopathy and DME Clinical Trials

Diabetic Retinopathy and Diabetic Macular Edema

Diabetic retinopathy (DR) stands as a significant cause of vision loss, particularly affecting the working-age population. In the United States alone, approximately eight million people are affected by this condition. DR arises as a complication of prolonged diabetes, resulting in damage to the delicate blood vessels and neural tissue of the retina.

Even in its early stages, DR impacts visual function, affecting contrast sensitivity, night vision, peripheral vision, and visual acuity. As the disease progresses, patients experience small hemorrhages throughout the retina, central retinal swelling, permanent loss of blood vessels, and the emergence of dangerous new blood vessels. These complications can lead to retinal detachment and severe glaucoma.

Thankfully, intervention can prevent or reverse these complications for the majority of patients. Treatment strategies often overlap with those used for wet macular degeneration. Ongoing research explores potential treatment options such as long-lasting molecules and cutting-edge gene therapy.

Below, we highlight some of the active studies at RCSD. Feel free to reach out to us to determine if any of these trials align with your needs.

Diabetic Retinopathy

DME